Updates in the Treatment of HR+/HER2- Breast Cancer - Episode 10

Toxicities and Treatment Selection of Endocrine-Based Therapies in HR+/HER2– Breast Cancer

February 11, 2025

Panelists discuss how genotype-directed treatment options compare with fulvestrant, factors influencing the choice of therapy, and strategies for managing adverse events with this class of therapies.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Diagnosis and Risk Stratification for Early-Stage HR+/HER2- Breast Cancer

EP. 2: CDK4/6 Inhibitors for HR+/HER2- Early Breast Cancer

EP. 3: Current Practices for Targeted Therapies and Molecular Testing for HR+/HER2- Metastatic Breast Cancer

EP. 4: Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies

EP. 5: Clinical Perspectives: Use of CDK4/6i After CDK4/6i

EP. 6: The Current Treatment Landscape of Oral SERDs in Metastatic Breast Cancer

EP. 7: Clinical Findings of Elacestrant, an Oral SERD for ER+/HER2– Metastatic Breast Cancer

EP. 8: Emerging Data of Additional SERDs in Metastatic Breast Cancer

EP. 9: CDK4/6 Inhibitors Plus Novel Agents for ER+/HER2–Advanced or mBC

Now Viewing

EP. 10: Toxicities and Treatment Selection of Endocrine-Based Therapies in HR+/HER2– Breast Cancer

EP. 11: Genotype-Directed Therapies for HR+/HER2– Advanced Breast Cancer

EP. 12: Exploring Data of PI3K/AKT/mTOR Inhibitors in HER2– mBC

EP. 13: Clinical Developments of Antibody-Drug Conjugates (ADCs) in HR+/HER2– mBC

EP. 14: ADCs: Recent Data of Dato-DXd from TROPION-Breast01

EP. 15: Impact of ADC Toxicities and Clinical Decision-Making for mBC

EP. 16: Continued Advances and Treatment Sequencing for HR+/HER2– Breast Cancer

Video content above is prompted by the following:

Dr. Bardia to All Panelists: How do these options compare? Why might you choose one of these options vs fulvestrant?

What are your strategies for AE adverse event management with this class of therapies?